Literature DB >> 14667097

Antiphospholipid antibodies and antiphospholipid syndrome in 57 children and adolescents with systemic lupus erythematosus.

L M A Campos1, M H Kiss, E A D'Amico, C A Almeida Silva.   

Abstract

The presence of antiphospholipid (aPL) antibodies and antiphospholipid syndrome (APS) was researched in 57 children and adolescents with systemic lupus erythematosus (SLE). The frequency of aPL antibodies was 75.4% (anticardiolipin 70.2% and lupus anticoagulant 29.1%). The positivity for these antibodies fluctuated during the course of the disease. No association was found between aPL antibodies and clinical or laboratory manifestations or the autoantibodies studied, nor with the activity or gravity of the SLE. APS was diagnosed in 14% of the cases (eight patients), on average three years after the diagnosis of SLE. Four patients had arterial thrombosis (stroke, three; transient ischaemic attack, one; amaurosis fugax, two; renal, one), one presented with deep vein thrombosis (DVT) and three had involvement of small calibre vessels (osteonecrosis, two; transverse myelitis, one). Recurrences were observed in three of the eight cases (37.5%), with a mean interval of 13 months between the events. The presence of APS was associated with haemolytic anaemia, leukopenia, thrombocytopenia, coagulation abnormalities, ischaemic cerebrovascular accidents, amaurosis fugax, osteonecrosis and interstitial pneumonitis. A negative association was observed between APS and the presence of anti-Ro antibodies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14667097     DOI: 10.1191/0961203303lu471oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  12 in total

Review 1.  Taxonomy for systemic lupus erythematosus with onset before adulthood.

Authors:  Clovis A Silva; Tadej Avcin; Hermine I Brunner
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-12       Impact factor: 4.794

2.  Antithrombotic therapy in neonates and children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 3.  Prevalence and burden of pediatric-onset systemic lupus erythematosus.

Authors:  Sylvia Kamphuis; Earl D Silverman
Journal:  Nat Rev Rheumatol       Date:  2010-08-03       Impact factor: 20.543

Review 4.  Pediatric antiphospholipid syndrome.

Authors:  Jacqueline A Madison; Yu Zuo; Jason S Knight
Journal:  Eur J Rheumatol       Date:  2019-12-03

5.  Pediatric APS: State of the Art.

Authors:  Arzu Soybilgic; Tadej Avcin
Journal:  Curr Rheumatol Rep       Date:  2020-03-03       Impact factor: 4.592

6.  Catastrophic antiphospholipid syndrome: first signs in the neonatal period.

Authors:  Marta Cabral; Clara Abadesso; Marta Conde; Helena Almeida; Helena Carreiro
Journal:  Eur J Pediatr       Date:  2011-08-16       Impact factor: 3.183

7.  Clinical characteristics and thrombosis outcomes of paediatric antiphospholipid syndrome: analysis of 58 patients.

Authors:  Jingran Ma; Hongmei Song; Min Wei; Yanyan He
Journal:  Clin Rheumatol       Date:  2017-07-26       Impact factor: 2.980

8.  Antiphospholipid antibodies in children with systemic lupus erythematosus: a long-term clinical and laboratory follow-up status study from northwest India.

Authors:  Jasmina Ahluwalia; Surjit Singh; Shano Naseem; Deepti Suri; Amit Rawat; Anju Gupta; Joseph Masih; Sunil Bose
Journal:  Rheumatol Int       Date:  2013-04-07       Impact factor: 2.631

Review 9.  Avascular necrosis in pediatric systemic lupus erythematosus: a brief report and review of the literature.

Authors:  Reut Gurion; Vin Tangpricha; Eric Yow; Laura E Schanberg; Grace A McComsey; Angela Byun Robinson
Journal:  Pediatr Rheumatol Online J       Date:  2015-04-23       Impact factor: 3.054

Review 10.  The Differences Between Childhood and Adult Onset Antiphospholipid Syndrome.

Authors:  Chris Wincup; Yiannis Ioannou
Journal:  Front Pediatr       Date:  2018-11-27       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.